several important ways. APCSC covers a wider geographical area, including studies from Australia and New Zealand (ANZ), which provide a 'Western' comparison group, as well as increasing numbers for certain pooled analyses. It uses individual participant, rather than summary, data, which allows for more flexible analyses. Also, it collects data on several risk factors for CVD, not just blood pressure and total cholesterol, and records all deaths, including those due to non-cardiovascular causes.
Initial funding was provided by the New Zealand Health Research Council and the Australian National Health and Medical Research Council (NHMRC). Twin Secretariats for APCSC were established at the Clinical Trials Research Unit at the University of Auckland, New Zealand and The George Institute for International Health at the University of Sydney, Australia. In later years, Pfizer Inc. of New York provided two substantial unrestricted educational grants to APCSC. Current funding is a mixture of pharmaceutical industry funding (Pfizer), peer reviewed research council funding (NHMRC; through a programme grant), and university funding (a University of Sydney cancer research award). The Secretariat and database are now solely housed within The George Institute.
What does it cover?
The primary aims of APCSC are to determine the age-specific, sex-specific, and region-specific (Asia and ANZ) associations of major cardiovascular risk factors with stroke (fatal and non-fatal, ischaemic and haemorrhagic), CHD (fatal and non-fatal), total CVD. Secondary outcomes are all-cause mortality and other major causes of death (e.g. cancer).
The primary analytical method is to use Cox proportional hazard regression models, adjusted for age and stratified by study (and where appropriate, sex) to calculate hazard ratios and confidence intervals. Continuous variables are adjusted for regression dilution error. 2 Who is in the sample?
Studies are eligible for inclusion in APCSC if they are based in the Asia Pacific region, use a cohort study design, and have at least 5000 person-years of follow-up. Individuals within each study are included if they have recordings, at baseline, of date of birth (or age), sex and blood pressure, and have vital status known at the end of follow-up, together with date of death (or the age at death) where applicable. Cohorts selected on the basis of a positive disease history, or diagnosis, are excluded.
Studies were identified by a range of methods, including searches of electronic databases (MEDLINE and EMBASE), scrutiny of abstracts and proceedings of meetings, and by personal enquiry among collaborators and colleagues. For each identified eligible study, the principal investigators (PIs) were invited to participate. Figure 1 shows the distribution of studies included in the APCSC database at the time of the third datalock, in April 2006 (previous datalocks were in 2000 and 2003) . Study names, and names of PIs, are given in the acknowledgements; this includes two studies that have agreed to join APCSC but have yet to qualify according to the entry criteria. The studies in Figure 1 are the only ones included in the remainder of this article.
How often have they been followed-up?
APCSC studies are free to contribute whatever data they like to the Collaboration. Of the 44 studies, 28 have only provided baseline data; 16 have additionally provided data on one repeat enumeration and six have contributed more than one repeat set of measurements, up to a maximum of seven repeats. The median follow-up is 6.7 years and the longest follow-up of any individual, not yet deceased, is 36 years.
What has been measured?
Baseline
As the primary outcomes in this collaboration are cardiovascular, the baseline risk factors collected are all the well-established risk factors for CVD. Table 1 gives a list of these risk factors, with numbers of individual data points. Methods used to measure risk factors varied; for instance 13 studies gave glucose from fasting samples and six from non-fasting. Wherever possible, methods and classifications were standardized. Several studies provided further variables, such as social classifications and ethnicity, but these were not consistently reported and are not amenable for analyses.
Repeat values
Values from repeat sampling have been provided for many continuous measures: the number of individuals with repeat measures for blood pressure 5 48 113, total cholesterol (n 5 21 575), HDL-cholesterol (n 5 7629), triglycerides (n 5 10 734), BMI (n 5 21 305), and glucose (n 5 4396). The median time to resampling was 3 years. From these data, regression dilution coefficients were calculated 2 using the MacMahon-Peto nonparametric method. 2, 3 These were 1.9 for systolic blood pressure, 2.1 for diastolic blood pressure, 1.7 for total cholesterol, 1.9 for HDL-cholesterol, 1.8 for triglycerides, 1.2 for BMI, and 1.6 for glucose.
Outcomes
Data on deaths were available for every study participant, according to the entry criteria. Figure 2 shows the underlying cause of death (taken as the sole cause of death in APCSC), where available. Different studies used different methods of coding, such as various incarnations of the International Classification of Diseases (ICD). Indeed, studies may have used different ICD codes in different periods. Some studies used rather broader classifications than others; hence, the proliferation of unknown classifications at lower levels in Figure 2 . Cause of death was unknown, or unreported, in 1021 (4%) of cases. Non-fatal events were requested for stroke (provided by 19 cohorts) and CHD (16 cohorts). Non-fatal stroke events by subtype were reported by 17 cohorts. Methods for obtaining information on non-fatal events differed across the studies but was mainly due to either self-report in repeat questionnaires or by review of medical records.
What has it found? Key findings and publications
At the time of writing, 21 papers have been published, or are about to be published, from APCSC, while more than a dozen further papers are in various stages of processing. The latter, unpublished research, includes reports on cancer outcomes. Published papers have shown that all the major cardiovascular risk factors work at least as strongly in Eastern as in Western populations. 4 Given the enormous size of the populations concerned, this result is important, since it implies that Western research and treatment regimens have relevance in Asia. Policies for prevention must, however, be specific to the populations, given the cultural differences even within Asia. Blood pressure seems to be a key risk factor for stroke and CHD in Asia, with hazard ratios, after adjusting for other risk factors, that are considerably greater than those in ANZ. 4 APCSC has
shown that blood pressure, 5 cholesterol, 6 and glucose 7 have log-linear relationships with CHD; results that often only become clear with large datasets. Most risk factors for CVD have been found to have greater hazard ratios in younger age groups and to work similarly between the sexes. An exception to the latter is diabetes; in this case APCSC data have helped to provide conclusive evidence of higher coronary relative risks in women. 8 What are the main strengths and weaknesses?
The great strengths of APCSC include the large amount of raw data and the strong collaboration, involving several ethnic groups. Day-to-day management is undertaken by a dedicated group in Sydney and the project is overseen by an Executive Committee, an elected representative group from across the countries involved. Three meetings of the entire collaboration have been held so far, as well as extra meetings of the Executive Committee. Some of the current funding has been used to hold a training workshop in Korea, with further funding earmarked for two similar workshops in China and Taiwan. Research publications are published in the name of the Collaboration, with writing committees that include representatives from across the geographical spread of APCSC. Language difficulties in China have been addressed by translating key documents, such as the regular APCSC newsletters, while five of the publications have been translated and submitted for re-publication in a Chinese medical journal. An APCSC website has been set up, with many special features available only to the collaborators. All these factors have helped maintain such a diverse collaboration for several years.
The main weaknesses of APCSC relate to nonstandardization of data collection methods. All the cohorts were begun before the Collaboration was initiated, without a common protocol. This has the potential to introduce bias when analysing continuous exposure variables, particularly when comparing subgroups that may be unequally distributed amongst the studies and makes analysis of categorical variables crude or impractical. Outcome variables have similar issues; for example, stroke subtypes are not always reported, are verified using different techniques in different studies (or at different times within the same study), and either do or do not include non-fatal events. Pooling studies with outcome data of such different quality and quantity requires assumptions, which may not always be well-founded.
Can I get hold of the data? Where can I find out more?
The data are held by the Sydney Secretariat and are not available for use by outsiders, including the sponsors. Members of the Collaboration who wish to work on the data have to do so in Sydney, having obtained prior approval from the Executive Committee. Further details on APCSC, including a full list of publications, are available from the Website: www. apcsc.info.
